Prognostic impact of WT1 dynamics in peripheral blood before and after allogeneic HSCT in patients with AML and MDS
A practical blood test tracking leukemia markers after bone marrow transplant predicts long-term survival without expensive technology.
In 51 AML/MDS patients undergoing allo-HSCT, serial WT1 peripheral blood monitoring defined three prognostically distinct groups, with WT1 negativity post-transplant strongly predicting relapse-free survival and overall survival. The finding supports WT1 dynamics as a practical, low-cost MRD monitoring approach in the post-HSCT setting where formal MRD tools are not always available.
What the study was
- Study design
- Retrospective cohort
- Population
- AML or MDS patients undergoing allo-HSCT, 2016–2025; n=51 analyzed
- Sample size
- 51
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- International Journal of Hematology
Why it surfaced
Relevant MRD monitoring data post-HSCT; small n=51 limits generalizability; single-center retrospective; WT1 as surrogate MRD marker has known specificity limitations.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.